

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2016

NEUROMETRIX, INC.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction
of incorporation)

001-33351

(Commission File Number)

04-3308180

(IRS Employer
Identification No.)

1000 Winter Street, Waltham, Massachusetts

(Address of principal executive offices)

02451

(Zip Code)

(781) 890-9989

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On October 31, 2016, NeuroMetrix, Inc. (the “Company”) provided an update to its corporate presentation in connection with the Sidoti Emerging Growth Convention at the Marriot Marquis in New York City on November 1, 2016, by posting the presentation to the Company’s website, www.neurometrix.com. The Company plans to use its website to disseminate future updates to its corporate presentation and does not intend to file or furnish a Form 8-K alerting investors each time the presentation is updated.

The information set forth in this Item 7.01 is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.

By filing this Current Report on Form 8-K and furnishing the information in this Item 7.01, the Company makes no admission as to the materiality of Item 7.01 in this report or the presentation available on the Company’s website. The information contained in the corporate presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Item, although it may do so from time to time as its management believes is appropriate or as required by applicable law. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, by updating its website or through other public disclosure.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Corporate Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEUROMETRIX, INC.

Date: October 31, 2016

/s/ THOMAS T. HIGGINS

Thomas T. Higgins
*Senior Vice President, Chief Financial Officer
and Treasurer*

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Corporate Presentation

NEUROMetrix[®]

Nasdaq: NURO

Shai N. Gozani, MD, PhD
President & CEO

Tom Higgins
Chief Financial Officer

November 2016

Overview


- Boston based healthcare company
- Founded in 1996 as spin-off from MIT
- Integrate bioelectrical and digital medicine to address chronic disease
- Premier R&D capabilities
- Experienced commercialization team
- Market a first-in-class over-the-counter wearable device to treat chronic pain
- High margin point-of-care diagnostic business



Chronic Pain Market

Large Opportunity with Many Unmet Needs


- 100M US adults, 1.5B worldwide
 - Low back pain, arthritis, diabetic nerve pain, fibromyalgia, cancer, CRPS, PHN, neck pain, facial pain
- \$600B annual cost in US¹
- \$35B global market²
- \$20B annual out-of-pocket spending in US³
- Over 200M opioid prescriptions in 2013⁴
- Unmet needs of chronic pain sufferers⁵
 - 51% little or no control over their pain
 - 59% impacts their overall enjoyment of life
 - 77% depressed
 - 86% unable to sleep well



¹Gaskin et al. 2012. ²Global market for pain management drugs and devices was valued at \$35.4 billion in 2012. BCC Research LLC.


³Nahin et al. 2015. ⁴National Institute of Drug Abuse. ⁵2006 Voices of Chronic Pain Survey (American Pain Foundation).

Quell Wearable Technology



- Wearable neurostimulator
- Widespread chronic pain relief
- Safe, no significant side effects
- Can be used 24/7
- App enabled
- Monitors therapy and health metrics

Quell Provides Therapeutic Benefit to 70-80% of Subjects



- **81%** of subjects reported improvement in chronic pain
- **67%** of subjects reported reduction in pain medication use


Gozani. Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of Chronic Low Back and Lower Extremity Pain. *Journal of Pain Research* 2016.

Ongoing Quell Clinical Studies

Title	Location(s)	Design	Status
Quell TENS band for Chemotherapy-Induced Peripheral Neuropathy	University of Rochester School of Medicine	Open Label (N=30)	50% enrolled Q2 '17 readout
Quell Opioid Reduction and Pain Relief in Patients With Cancer	Scripps Translational Science Institute	Randomize, sham controlled (N=40)	35% enrolled Q3 '17 readout
Efficacy of the Quell Wearable Device for Chronic Low Back Pain	Brigham and Women's Hospital, Harvard Medical School	Randomized, standard therapy controlled (N=60)	Enrollment to start Q4 '17 readout



Market Opportunity of 19M Chronic Pain Sufferers



Market opportunity estimate independently developed by Connelly Partners (Boston, MA) using Nielsen MRI data. 2016.

Quell Pricing




Quell Starter Kit
\$249






Replacement Electrodes
\$29.95


North America Quell Distribution



Quell Demonstrating Consistent Growth



Consumers Report Positive Experience With Quell



Tabulated August 27, 2016


Expected average rating based on clinical efficacy and return rate (75% with 4 or 5 stars and 25% with 1 or 2 stars).

Quell has Limited Direct Competition

- Many OTC and Rx options for chronic pain
- Attractive space so constant flow of new products and entrants
- Chronic pain sufferers utilize multiple treatments (“toolbox”)
- Quell is only wearable designed and powered for chronic pain
- Quell stands out on efficacy, safety and innovation


Pain Relief Product Categories	Key Distinction with Quell
OTC TENS	Localized low-dose pain relief, no app or digital health
Spinal Cord Stimulators	Expensive device and surgery
Light therapy, Ultrasound	Localized pain relief
Herbals and Nutraceuticals	Variable efficacy
OTC Pain Medications (e.g., NSAIDs)	Side effects
Rx Pain Medications (e.g., opioids)	Side effects

Quell is More Powerful than OTC TENS



- Quell generates **5x** greater energy at same stimulation current
- Quell has **15x** greater maximum energy

Upcoming Catalysts



Financials

2015 Financial Highlights (000's)

(\$000's)	Q3 2016	Q2 2016	Q1 2016	2015	2014	2013
Revenue	\$3,389	\$2,647	\$2,275	\$7,300	\$5,513	\$5,279
- Quell	\$2,086	\$1,635	\$1,206	\$2,091	\$0	\$0
- Diagnostics	\$783	\$451	\$477	\$2,293	\$1,804	\$1,259
- Legacy Products	\$520	\$560	\$590	\$2,916	\$3,709	\$4,020
Margin	40.1%	40.6%	34.8%	45.9%	53.4%	58.4%
OPEX	\$5,328	\$5,252	\$4,989	\$16,625	\$11,714	\$10,443
Cash Usage	\$3,762	\$4,204	\$3,647	\$13,694	\$7,906	\$6,641
- Cash	\$7,568	\$11,330	\$8,740	\$12,463	\$9,222	\$9,196
- Debt	none	none	none	none	none	none

Market Valuation (Oct 26, 2016)	
Outstanding	5,318,273
Preferred, as-converted	10,982,929
	16,301,202
Recent Closing Price	\$1.36
Market Value	\$22,169,635

Management Team



Shai N. Gozani, MD., PhD.
*President, CEO
 and Founder*



- 10+ years public company CEO
- Background in medicine, engineering and neuroscience



Thomas T. Higgins
SVP and CFO



- Extensive public company CFO experience
- Strong operational background



Frank McGillin
*SVP and General
 Manager, Consumer*



- 20+ years consumer health care experience
- Deep sales, marketing and operational background

Investment Highlights

- Commercial stage healthcare company combining bioelectrical and digital medicine to address chronic disease
- Market a first-in-class over-the-counter wearable device to treat chronic pain
- Razor/razor-blade business model with good sales growth in first 6 quarters
- Profitable point-of-care diagnostic business that may be monetized
- Experienced management team

